Mesoblast also intends to provide FDA with additional potency assay data for RYONCIL product manufactured using the current FDA-inspected process, linking product which was used in the pediatric Phase 3 trial, which met its primary endpoint, with product which will be used in the proposed registration Phase 3 trial in adults. Showing that the product used in the pediatric and adult trials is standardized, together with data showing that future product is well characterized for commercial release, could support approval for the pediatric indication given the absence of any approved therapies for children.
Has this been announced before.
He might think he can get there without a raise.
Maybe. lol
Aloha.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-14
-
- There are more pages in this discussion • 349 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.48 |
Change
0.105(7.64%) |
Mkt cap ! $1.689B |
Open | High | Low | Value | Volume |
$1.40 | $1.49 | $1.38 | $8.181M | 5.685M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 25443 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.48 | 60811 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 25443 | 1.460 |
9 | 126101 | 1.455 |
2 | 19977 | 1.450 |
2 | 47643 | 1.445 |
1 | 18977 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.480 | 60811 | 4 |
1.485 | 70703 | 4 |
1.490 | 209218 | 9 |
1.495 | 312041 | 9 |
1.500 | 528708 | 27 |
Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online